Head of GSK in China is replaced as details of fraud scandal emergeBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4791 (Published 29 July 2013) Cite this as: BMJ 2013;347:f4791
- Jane Parry
- 1Hong Kong
GlaxoSmithKline has replaced the head of its China operations, Mark Reilly, who left the country before four senior executives were detained as part of a criminal investigation into alleged corruption.
Hervé Gisserot, the company’s vice president for Europe, will now take the helm in China. The travel ban on GSK’s finance director, Steve Nechelput, has also been lifted.
Abbas Hussain, GSK’s president for Europe, Japan, emerging markets, and Asia Pacific, met with officials from China’s Ministry of Public Security. In a subsequent statement on 22 July, Hussain reiterated GSK’s commitment to rooting out corrupt behaviour by its employees.
“We will actively look at our business …
Log in using your username and password
Log in through your institution
Sign up for a free trial